Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
104 hedge funds and large institutions have $411M invested in Marinus Pharmaceuticals, Inc in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 30 reducing their positions, and 19 closing their positions.
705% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $1.53M
37% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 30
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 106 → 104 (-2)
15% less capital invested
Capital invested by funds: $485M → $411M (-$73.9M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$20.5M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$11.3M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$9.54M |
| 5 |
Jennison Associates
New York
|
+$9.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.7M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$4.24M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.86M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.16M |
MRNS Hedge Fund Activity: Q3 2023 in Review
104 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2023, worth a combined $411M — down 15% from $485M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MRNS and 18 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 41 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $21.8M. The largest seller was Logos Global Management, exiting entirely with an estimated $5.7M sold.
- 104 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2023, down from 106 in Q2 2023.
- Funds reported $411M of Marinus Pharmaceuticals, Inc stock for Q3 2023, down 15% quarter-over-quarter.
- 18 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2023 and 19 closed out, a net change of -1 holder.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2023 was Cormorant Asset Management, an estimated $21.8M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2023 was Logos Global Management, an estimated $5.7M sold.
Based on aggregated 13F filings for Q3 2023.